View More Recent Stories

Dec 23, 2015 11:45AM OSE Pharma Announces Selection of 70 International Clinical Centers to Participate in Its Pivotal Phase 3 Trial of Tedopi® for Patients Diagnosed with Advanced Non-Small Cell Lung Cancer (NSCLC)
Dec 14, 2015 11:45AM OSE Pharma to Participate to Biotech Showcase™ During JP Morgan Healthcare Conference
Dec 7, 2015 11:45AM OSE Pharma Admitted to Long-Only Deferred Settlement Service
Nov 19, 2015 11:45AM OSE Pharma Successfully Completes the Manufacturing of the Clinical Batches for Its Pivotal Phase 3 Clinical Trial with Tedopi®
Nov 2, 2015 02:00AM OSE Pharma receives positive opinion from several European countries to start pivotal Phase 3 trial of Tedopi®
Oct 20, 2015 11:45AM OSE Pharma to attend BIO-Europe 2015
Sep 16, 2015 11:45AM OSE Pharma Enters Euronext Index CAC® Small, CAC® Mid & Small and CAC® All-Tradable
Sep 14, 2015 11:45AM Ose Pharma to Attend BioPharm America September 15th to 16th, 2015, Boston, United-States
Sep 10, 2015 11:45AM OSE Pharma SA: Results for the First Half of 2015 in Line with Forecasts and Major Clinical Advances
Sep 9, 2015 01:00AM OSE PHARMA unveils Clinical and immunological outcomes in patients with brain metastases treated with Tedopi® in a phase 2 trial presented at the World Conference on Lung Cancer (WCLC) in Denver, USA
View More Recent Stories